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Background:  This  experimental  study  examined  the  effect  of  the  antioxidant  drug “U-74389G”,  on  a rat
model  and particularly  in  a hypoxia  – reoxygenation  protocol.  The  effects  of that  molecule  were  studied
hematologically  using  blood  mean  platelets  volume  (MPV)  levels.
Methods:  40  rats  of  mean  weight  231.875  g were used  in  the  study.  MPV  levels  were  measured  at  60  min
of  reoxygenation  (groups  A and  C) and  at 120  min  of reoxygenation  (groups  B and  D).  The  drug  U-74389G
was  administered  only  in  groups  C  and  D.
Results: U-74389G  administration  kept  signiﬁcantly  increased  the  predicted  MPV  levels  by 12.77 ±  3.07%
(p =  0.0001).  Reoxygenation  time  non-signiﬁcantly  decreased  the  predicted  MPV  levels  by 2.55  ±  3.71%
(p =  0.4103).  However,  U-74389G  administration  and  reoxygenation  time  together  kept  signiﬁcantly
increased  the  predicted  MPV  levels  by 7.09  ± 1.91%  (p =  0.0005).eoxygenation
ean platelets volume Conclusions:  U-74389G  administration  whether  it interacted  or not  with  reoxygenation  time  kept  signif-
icantly  increased  the  predicted  MPV  levels.  This  ﬁnding  has  great  clinical  interest  in  blood  clotting  and
coagulation  pathophysiology.
©  2016  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
en  acS.L.U.  This  is an op
ntroduction
Transient or permanent damage with serious implications on
djacent organs and systems may  be due to tissue hypoxia –
eoxygenation (HR). The use of U-74389G in HR has been a
hallenge for many years. However, although the progress was
igniﬁcant, several practical affairs have not been clariﬁed. They
nclude: (a) how potent U-74389G should be (b) when should
t be administered and (c) at what optimal dose U-74389G
hould be administered. The promising effect of U-74389G in tis-
ue protection has been noted in several HR studies. U-74389G
r also known as 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-
iperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt is an
ntioxidant which prevents both arachidonic acid-induced and
ron-dependent lipid peroxidation.1 It protects against ischemia
 reperfusion (IR) injury in organs such as animal hearts, livers
∗ Corresponding author at: Department of Obstetrics & Gynecology, Mesologi
ounty Hospital, Nafpaktou Street, Mesologi 30200, Etoloakarnania, Greece.
E-mail address: Tsomposconstantinos@gmail.com (C. Tsompos).
http://dx.doi.org/10.1016/j.pbj.2016.10.003
444-8664/© 2016 PBJ-Associac¸a˜o Porto Biomedical/Porto Biomedical Society. Publishe
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).cess  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
and kidneys. These membrane-associating antioxidants are par-
ticularly effective in preventing permeability changes in brain
microvascular endothelial cells monolayers.2 A meta-analysis of
25 published seric variables, as WBC, RBC and platelet counts,
hematocrit, hemoglobin, MCH, MCHC, RbcDW, platelet-crit, PDW,
glucose, creatinine, uric acid, total protein, GT, ALP, ACP, CPK, LDH,
sodium, potassium, chloride, calcium, phosphorus and magne-
sium levels coming from the same experimental setting, enhanced
by 0.48 ± 17.28% (p-value = 0.2377) their total catabolism after U-
74389G administration for the same endpoints.7,8 The studied
molecule U-74389G belongs to a wider family of other similar
antioxidant molecules; all used in several published trials.
Mean platelet volume (MPV) is a machine-calculated measure-
ment of the average size of platelets found in blood and is typically
included in blood tests as part of the complete blood count one.
Since the average platelet size is larger when the body is pro-
ducing increased numbers of platelets, the MPV  test results can
be used to make inferences about platelet production in bone
marrow or platelet destruction problems. MPV  is higher when
there is destruction of platelets. This may  be seen in inﬂamma-
tory bowel disease,3 immune thrombocytopenic purpura (ITP),
d by Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND
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Table 1
Weight and mean platelet volume levels and Std. Dev. of groups.
Groups Variable Mean Std. dev
A Weight 243 g 45.77724 g
A  MPV 6.15 ﬂ 0.347211 ﬂ
B  Weight 262 g 31.10913 g
B  MPV 6.51 ﬂ 0.4433459 ﬂ
C  Weight 212.5 g 17.83411
C  MPV 8.78 ﬂ 2.078889 ﬂ
D  Weight 210 g 18.10463 g
D  MPV 8.92 ﬂ 1.917638 ﬂ
MPV, mean platelet volume; Std. Dev, standard deviation.
Table 2
Statistical signiﬁcance of mean values difference for groups (DG) after statistical
standard t test application.
Variable Difference p-value
A–B Weight −19 g 0.2423
A–B MPV  −0.36 ﬂ 0.0820
A–C  Weight 30.5 g 0.0674
A–C  MPV  −2.63 ﬂ 0.0049
A–D  Weight 33 g 0.0574
A–D  MPV  −2.77 ﬂ 0.0024
B–C  Weight 49.5 g 0.0019
B–C MPV −2.27 ﬂ 0.0080
B–D  Weight 52 g 0.0004
B–D  MPV  −2.41 ﬂ 0.0045
C–D  Weight 2.5 g 0.7043C. Tsompos et al. / Porto 
yeloproliferative diseases and Bernard–Soulier syndrome. It may
lso be related to pre-eclampsia and recovery from transient
ypoplasia.4 Abnormally low MPV  values correlate with throm-
ocytopenia when it is due to impaired production as in aplastic
nemia. In addition, low MPV, can correlate with abnormally small
latelet size, sometimes a symptom of a spectrum referred to as
iskott–Aldrich Syndrome,5 caused by a genetic mutation of the
AS  gene. A typical range of platelet volumes is 9.7–12.8 femtolitre
fL), equivalent to spheres 2.65–2.9 m in diameter. Normal range
s given as 7.5–11.5 fL.6 The aim of this experimental study was
o examine the effect of the antioxidant drug “U-74389G” on rat
odel and particularly in a hypoxia-reoxygenation HR protocol.
he effects of that molecule were studied by measuring blood MPV
evels.
aterials and methods
nimal preparation
This biomedical research was licensed by Veterinary Address of
ast Attiki Prefecture based on 3693/12-11-2010 & 14/10-1-2012
ecisions. All substances, consumables and equipment were a grant
f Experimental Research Centre of ELPEN Pharmaceuticals Co. Inc.
.A. at Pikermi, Attiki. Appropriate humanistic care was adopted
or Albino female Wistar rats. Pre-experimental normal housing
ncluded ad libitum diet in laboratory for one week. Animals’ pre-
arcosis was preceded of continuous intra-experimental general
nesthesia,7,8 oxygen supply, electrocardiogram and acidome-
ry. Euthanasia did not permit post-experimental awakening and
reservation of animals. Rats were randomly delivered to four
xperimental groups by 10 animals in each one, using following
rotocols of HR: Hypoxia for 45 min  followed by reoxygenation for
0 min  (group A); hypoxia for 45 min  followed by reoxygenation
or 120 min  (group B); hypoxia for 45 min  followed by immedi-
te U-74389G intravenous (IV) administration and reoxygenation
or 60 min  (group C); hypoxia for 45 min  followed by immedi-
te U-74389G IV administration and reoxygenation for 120 min
group D). The dose of U-74389G was 10 mg/kg body mass of ani-
als. Hypoxia was caused by laparotomic clamping inferior aorta
ver renal arteries with forceps for 45 min. The clamp removal re-
stablished the inferior aorta patency and restored reoxygenation.
-74389G was administered at the time of reperfusion; through
atheter of inferior vena cava. The MPV  levels were determined at
0th min  of reoxygenation (for A and C groups) and at 120th min  of
eoxygenation (for B and D groups). The sampling was performed
fter vena cava venipuncture by ﬁlling a 2 cc dimpled control stroke
yringe with pre-set volume for withdrawal and sterile insulin nee-
le. Then, the sample was transferred to vacuum blood collection
ube (disposable vacutainer) of 2 ml  containing K2EDTA, the “anti-
oagulant of choice in specimen collection and blood cell features
ounting” according to both NCCLS and the International Council
or Standardization in Hematology. MPV  levels measurements were
erformed by Nihon Kohden celltac a MEK-6450 K automatic hema-
ology analyzer with pre-set rat type and cyanide-free reagents.
ourty female Wistar albino rats were used (mean weight 231.875 g
Standard Deviation (SD): 36.59703 g], with minimum weight 165 g
nd maximum weight 320 g. Rats’ weight could be potentially a
onfusing factor, e.g. more obese rats to have higher MPV  levels.
his assumption was also investigated.ontrol groups
20 control rats (mean mass 252.5 g [SD: 39.31988 g]) experi-
nced hypoxia for 45 min  followed by reoxygenation.C–D  MPV  −0.14 ﬂ 0.6091
MPV, mean platelet volume; DG, difference for groups.
Group A
Reoxygenation lasted for 60 min  (n = 10 controls rats) mean
mass 243 g [SD: 45.77724 g], mean MPV  levels 6.15 ﬂ [SD:
0.347211 ﬂ] (Table 1).
Group B
Reoxygenation lasted for 120 min  (n = 10 controls rats) mean
mass 262 g [SD: 31.10913 g], mean MPV  levels 6.51 ﬂ [SD:
0.4433459 ﬂ] (Table 1).
Lazaroid (L) group
20 L rats (mean mass 211.25 g [SD: 17.53755 g] experienced
hypoxia for 45 min  followed by reoxygenation in the beginning of
which 10 mg  U-74389G/kg body weight were IV administered.
Group C
Reoxygenation lasted for 60 min  (n = 10 L rats) mean mass
212.5 g [SD: 17.83411 g], mean MPV  levels 8.78 ﬂ [SD: 2.078889 ﬂ]
(Table 1).
Group D
Reoxygenation lasted for 120 min  (n = 10 L rats) mean mass
210 g [SD: 18.10463 g], mean MPV  levels 8.92 ﬂ [SD: 1.917638 ﬂ]
(Table 1).
Statistical analysis
Every weight and MPV  level group was  compared with each
other by statistical standard t-tests (Table 3). Any signiﬁcant dif-
ference among MPV  levels, was  investigated whether owed in any
potent signiﬁcant weight one. The application of generalized linear
models (glm) with dependant variable the MPV  levels was fol-
lowed. The 3 independent variables were the U-74389G or no drug
administration, the reoxygenation time and both variables in com-
bination. Inserting the rats’ weight also as an independent variable
at glm analysis, a signiﬁcant relation resulted in (p = 0.0033), so as
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Table 3
The increasing inﬂuence of U-74389G in connection with reoxygenation time.
Increase 95% c. in. Reoxygenation
time
t-test p-value
glm
2.63 ﬂ 1.229718 ﬂ to 4.030282 ﬂ 1 h 0.0049 0.0009
2.52  ﬂ 1.617097 ﬂ to 3.422903 ﬂ 1.5 h 0.0000 0.0000
2.41  ﬂ 1.102374 ﬂ to 3.717626 ﬂ 2 h 0.0045 0.0011
0.25 ﬂ −0.9720322 ﬂ to 1.472032 ﬂ Reoxygenation
time
0.1317 0.6811
1.4  ﬂ 0.8219751 ﬂ to 1.978025 ﬂ Interaction – 0.0000
c. in., conﬁdence interval.
Table 4
Predicted mean platelet volume levels and Std. Dev. of groups.
Groups Mean Std. Dev.
A 7.329363 ﬂ 1.072472 ﬂ
B  6.88423 ﬂ 0.7288264 ﬂ
C  8.043919 ﬂ 0.4178185 ﬂ
D  8.102489 ﬂ 0.4241564 ﬂ
MPV, mean platelet volume; Std. Dev., standard deviation.
Table 5
Statistical signiﬁcance of predicted mean platelet volume values difference for
groups (DG) after statistical standard t test application.
DG Difference p-value
A–B 0.4451332 ﬂ 0.2423
A–C  −0.7145558 ﬂ 0.0674
A–D  −0.7731257 ﬂ 0.0574
B–C  −1.159689 ﬂ 0.0019
B–D  −1.218259 ﬂ 0.0004
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Table 7
The (%) predicted increasing inﬂuence of U-74389G in connection with reoxygena-
tion time.
Increase ±SD Reoxygenation time p-values
+9.29% ±5.07% 1 h 0.0663
+12.77% ±3.07% 1.5 h 0.0001
+16.25% ±3.81% 2 h 0.0003
−2.55% ±3.71% Reoxygenation time 0.4103
T
T
cC–D  −0.05857 ﬂ 0.7043
G, difference for groups.
o further investigation was  needed. The predicted MPV  values for
eight were calculated and are depicted at Table 4. The differences
etween predicted MPV  values groups calculated by standard t test
re depicted at Table 5. The application of generalized linear mod-
ls (glm) with dependant variable the predicted MPV  levels was
ollowed. The 3 independent variables were the same as in the ﬁrst
lm analysis.
esults
The ﬁrst glm resulted in: U-74389G administration kept signif-
cantly increased the MPV  levels by 2.52 ﬂ [1.617097–3.422903 ﬂ]
p = 0.0000). This ﬁnding was in accordance with the results
f standard t-test (p = 0.0000). Reoxygenation time kept non-
igniﬁcantly increased the MPV  levels by 0.25 ﬂ [−0.9720322 ﬂ to
.472032 ﬂ] (p = 0.6811), also in accordance with standard t-test
p = 0.1317). However, U-74389G administration and reoxygena-
ion time together kept signiﬁcantly increased the MPV  levels by
.4 ﬂ [0.8219751–1.978025 ﬂ] (p = 0.0000). Reviewing the above
nd Table 2, Table 3 sums up concerning the increasing inﬂuence of
-74389G in connection with reoxygenation time. The second glm
able 6
he predicted increasing inﬂuence of U-74389G in connection with reoxygenation time.
Increase 95% c. in. 
+0.7145558 ﬂ −0.0501243 ﬂ to 1.479236 ﬂ 
+0.9664074 ﬂ 0.5098173 ﬂ to 1.422997 ﬂ
+1.218259 ﬂ 0.6580188 ﬂ to 1.778499 ﬂ 
−0.1932816 ﬂ −0.7457019 ﬂ to 0.3591387 ﬂ 
+0.5377804 ﬂ 0.2527449 ﬂ to 0.8228159 ﬂ 
. in., conﬁdence interval.+7.09% ±1.91% Interaction 0.0005
SD, standard deviation.
resulted in: U-74389G administration kept signiﬁcantly increased
the predicted MPV  levels by 0.9664073 ﬂ [0.5098173–1.422997 ﬂ]
(p = 0.0001). This ﬁnding was  in accordance with the results
of standard t-test (p = 0.0002). Reoxygenation time kept non-
signiﬁcantly decreased the predicted MPV  levels by 0.1932816 ﬂ
[−0.7457019 ﬂ to 0.3591387 ﬂ] (p = 0.4831), also in accordance with
standard t-test (p = 0.3375). However, U-74389G administration
and reoxygenation time together kept signiﬁcantly increased the
predicted MPV  levels by 0.5377804 ﬂ [0.2527449–0.8228159 ﬂ]
(p = 0.0005). Reviewing the above and Table 5, Tables 6 and 7 sum
up concerning the increasing inﬂuence of U-74389G in connection
with reoxygenation time on predicted MPV  levels.
Discussion
Hypoxia may  inﬂuence MPV  levels. Ghahremanfard et al.
associated9 MPV  levels with ﬁrst acute ischemic stroke severity
grading (p = 0.012). Isik et al. correlated10 the MPV levels ranged
from 6.5 fL to 11.7 fL, with slow coronary ﬂow (p = 0.03). Balcik
et al. measured11 MPV  values signiﬁcantly higher at 24 h after pro-
gression of ischemic stroke (p = 0.001) than control participants.
Damaske et al. indicated12 increased MPV  levels in slow coronary
ﬂow phenomenon than control ones. Ertas¸ et al. observed13 an
increase in MPV  levels in chronic heart failure as an independent
predictor of mortality than (p = 0.004) in control group. Ac¸ ikgöz
et al. noted14 signiﬁcantly higher MPV  values in ischemic car-
diomyopathies than control ones (p < 0.001). Ntaios et al. related15
the signiﬁcantly increased MPV  levels in acute ischemic non-
lacunar stroke with poor functional outcome 24 h after. Slavka et al.
indicated16 that an increased MPV  value (≥11.01 fL) creates higher
risk for ischemic heart disease. Ilhan et al. found17 signiﬁcant dif-
ferences of MPV  levels in symptomatic lacunar stroke infarct group
than control one (p < 0.01). Mayda-Domac¸ et al. associated18 the
MPV levels as independent risk factors with ischemic, hemorrhagic
stroke and a bad prognosis (p = 0.007). Pikija et al. associated19
higher MPV  levels with larger infarct volume and greater risk of
late death/dependence rates (p = 0.048) in acute ischemic stroke.
Durmaz et al. found20 MPV  levels higher in the aspirin non-
responder stable coronary artery disease patients than responder
ones. Yetkin21 and Muscari et al. associated22 MPV  levels with
ischemic electrocardiographic changes in elderly population. Bit-
igen et al. found23 signiﬁcantly higher isolated coronary artery
ectasia (CAE) MPV  values than control ones (p < 0.0001). Ihara et al.
profoundly related24,25 MPV  levels in patients with ischemic heart
Reoxygenation time t-test p-values
glm
1 h 0.0674 0.0653
1.5 h 0.0001 0.0002
2 h 0.0004 0.0002
Reoxygenation time 0.3375 0.4831
Interaction - 0.0005
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isease but non in angiographically negative group than in pos-
tive one. Nadar et al. found26 lower MPV  levels in acute stroke
nd on follow-up, but higher mean MPV  ones in uncomplicated
ypertensive patients than control ones. McCabe et al. found27
eticulated platelets larger than more mature ‘non-reticulated’
latelets in ischemic cerebrovascular disease (p < 0.01). Greiseneg-
er et al. associated28 the MPV  levels with higher risk of severe
troke and worse outcome (p = 0.013). O’Malley et al. found29 MPV
evels higher 48 h after an acute stroke (p < 0.001), in available sur-
ivors and in both acute and chronic (>6 months) phase of cerebral
schemia preceded of vascular event. Kristensen et al. assessed30
he increased MPV  level as risk factor for acute phase of MI  patients
nd death. Legrand et al. described31 the in vitro platelet fragmen-
ation in the circulation of patients with ischemic cerebrovascular
isease. Dudley et al32 distinguished primary thrombocythemia
rom reactive thrombocytosis by MPV  levels. Although the frag-
ented discussion with the successive analysis of more than 25
tudies, the constant outcome is the narrow association of high
PV  values with ischemia proved across all of them. The MPV
alues role cannot be dissociated with platelet count, coagulation
hysiology and blood clotting. Indeed, U-74389G administration
ecreases the platelet count short-term by different signiﬁcance
evels, exerting a potent beneﬁcial effect on the range of all throm-
otic situations. Furthermore, Fang et al. associated33 the increase
n MPV  values with increased platelet distribution, prothrombin
ime, activated partial thromboplastin time, thrombin time, pro-
hrombin ratio, international normalized ratio, blood clotting time
nd platelet anti-aggregation, but with decreased PT%, ﬁbrinogen
evel, platelet aggregation (p < 0.05), platelet count and platelet-crit
n rats. Qureshi et al. demonstrated34 a dose-dependent anticoag-
lation effect with signiﬁcantly (p < 0.0002) prolonged coagulation
ime, bleeding time, prothrombin time, activated partial throm-
oplastin time, international normalized ratio and MPV  values,
hile plasma calcium concentration and mean platelet count were
igniﬁcantly decreased (p < 0.001). Yuce et al. considered the35
arger platelets hemostatically more reactive than normal size ones,
ncreasing the propensity to thrombosis. Ouyang et al. showed36
hat the plasma clotting time induced by cryopreserved fresh
latelet-rich plasma was signiﬁcantly shorter than that induced
y fresh platelet-rich plasma, evaluating the MPV  variable. Tei-
el identiﬁed the aetiological mechanism as hypoproliferative or
onsumptive37 for impaired ﬁbrin clot formation and delayed
leeding after primary haemostasis characteristic of hyperﬁbrinol-
sis; after examination of the MPV  morphology. van der Planken
t al. found38 no difference in MPV  between diabetic and con-
rol platelet-rich plasma. The outer layer of platelet phospholipid
embrane is more procoagulant than in the quiescent state, stimu-
ating thrombin formation in plasma. This platelet function is called
latelet procoagulant activity. Gunsilius et al. calculated39 the VEGF
ontent per 109 platelets at 2.51 ± 2.39 pg and as dependent on
he MPV  values. Van der Planken et al. associated40 the higher
PV values of buffy coat method (BCM) concentrates (p < 0.0005)
ith higher platelet procoagulant activity than the MPV  ones of
latelet-rich method concentrates at any storage day. Nelson et al.
easured41 signiﬁcantly increased MPV  values (p < 0.01); short-
ned prothrombin time by 1 s (p < 0.01) during the consumption
eriod of dietary n−3 fatty acids salmon diet. van Wersch et al.
ound42 a signiﬁcant decrease of the platelet count, MPV  levels
nd total thrombocytic clotting capacity. Mammen et al. found43
 marked post-operational increase in all clotting factors and
easured near normal levels 48 h after cardiopulmonary bypass
peration. Platelet counts remained low, however; the decrease
n factors rarely dropped so as to compromise hemostasis (<30%).
lthough antithrombin levels decreased below 60%, no difﬁculties
ith heparinization were encountered. A signiﬁcant drop in MPV
evels was recorded only after protamine administration; restoredd. J. 2016;1(5):186–190 189
24 h post-operatively. The MPV  levels are considered a rather
insigniﬁcant variable when evaluating the clotting situations. The
above literature has shown that the role of MPV  variable is not sub-
ordinate than other platelet characteristics and should be taken into
consideration when assessing the clotting proﬁles. Although the
information given by all these separate studies is constant, even in
combination with platelet count, coagulation physiology and blood
clotting; it cannot be integrated, it is ambiguous and not clear:
while the MPV  augmentations increase the hemostatic reactivity
and associate the ischemic situations, the coagulation is attenuated.
The U-74389G administration seems to enhance this phenomenon
since it increases the MPV  levels. How ischemia can compromise
with anticoagulation by the same drug has difﬁcult answer. Never-
theless, the investigation of the clotting process dominant direction
is very complicated studied individually only by the MPV  variable.
This direction cannot be predicted by any critical analysis, perhaps
due to the size, limits and constrains of the present experiment.
However, the effect of U-74389G at other platelet features such
as the platelet counts is attenuating, causing also anticoagulation
trend. The resultant effect of U-74389G on the clotting tendency of
blood can be determined only by the most appropriate assays eval-
uating the extrinsic pathway of coagulation. These assays which
unpleasantly were not included in the present experiment are the
prothrombin time (PT), the prothrombin ratio (PR) and the inter-
national normalized ratio (INR) that must be evaluated in a future
experiment.
Conclusion
U-74389G administration whether it interacted or not with
reoxygenation time kept signiﬁcantly increased the predicted MPV
levels in the short term prospect of this experiment. However, the
total clotting effect of U-74389G can be revealed only after the PT,
PR and the INR evaluation inclusion in a future experiment.
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